evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

175 questions · 177 findings · 29 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 32 · 18.1%GRADE not reported 13 · 7.3%Very low 49 · 27.7%Low 54 · 30.5%Moderate 25 · 14.1%High 4 · 2.3%

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from DEPOT‐medium term (3‐12 months)

Adverse effects: serious · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from DEPOT‐medium term (3‐12 months)

Satisfaction with care: Loss to · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems

It is very uncertain whether SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN changes satisfaction with care: Loss to compared with CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from… (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Clinical relapse · relapsing multiple sclerosis

Rituximab as 'switching' may leads to lower relapse measured by clinical assessment over 12 months compared with placebo (low certainty).

1 finding from 1 review

Rituximab vs placebo

Serious adverse events measured by clinical assessment over 12 months · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes serious adverse events measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Common infections measured by clinical assessment over 12 months · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes common infections measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Cancer · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes cancer measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Mortality measured by clinical assessment over 12 months · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes mortality measured by clinical assessment over 12 months compared with placebo (very low certainty).

1 finding from 1 review